88 related articles for article (PubMed ID: 38550534)
1. Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid overdose on respiratory depression and cardiac arrest.
Laffont CM; Purohit P; Delcamp N; Gonzalez-Garcia I; Skolnick P
Front Psychiatry; 2024; 15():1399803. PubMed ID: 38952632
[TBL] [Abstract][Full Text] [Related]
2. Whole body physiology model to simulate respiratory depression of fentanyl and associated naloxone reversal.
Baird A; White SA; Das R; Tatum N; Bisgaard EK
Commun Med (Lond); 2024 Jun; 4(1):114. PubMed ID: 38866911
[TBL] [Abstract][Full Text] [Related]
3. The pattern of brain oxygen response induced by intravenous fentanyl limits the time window of therapeutic efficacy of naloxone.
Curay CM; Irwin MR; Kiyatkin EA
Neuropharmacology; 2023 Jun; 231():109507. PubMed ID: 36940812
[TBL] [Abstract][Full Text] [Related]
4. High-Dose Naloxone Formulations Are Not as Essential as We Thought.
Lemen PM; Garrett DP; Thompson E; Aho M; Vasquez C; Park JN
medRxiv; 2023 Aug; ():. PubMed ID: 37645849
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of C
Kassick AJ; Treat A; Tomycz N; Feasel MG; Kolber BJ; Averick S
RSC Med Chem; 2022 Feb; 13(2):175-182. PubMed ID: 35308026
[TBL] [Abstract][Full Text] [Related]
6. Covalent Poly(lactic acid) Nanoparticles for the Sustained Delivery of Naloxone.
Kassick AJ; Allen HN; Yerneni SS; Pary F; Kovaliov M; Cheng C; Pravetoni M; Tomycz ND; Whiting DM; Nelson TL; Feasel M; Campbell PG; Kolber B; Averick S
ACS Appl Bio Mater; 2019 Aug; 2(8):3418-3428. PubMed ID: 31497753
[TBL] [Abstract][Full Text] [Related]
7. Functionalized Gold Nanoparticles and Halogen Bonding Interactions Involving Fentanyl and Fentanyl Derivatives.
Sherard MM; Kaplan JS; Simpson JH; Kittredge KW; Leopold MC
Nanomaterials (Basel); 2024 May; 14(11):. PubMed ID: 38869542
[TBL] [Abstract][Full Text] [Related]
8. Corrigendum to "Co-administration of naloxone and dexmedetomidine to simultaneously reverse acute effects of fentanyl and methamphetamine in rats" [Drug Alcohol Depend. 259 (2024) 111301].
Tackett WR; Yalakala J; Hambuchen MD
Drug Alcohol Depend; 2024 Jun; ():111380. PubMed ID: 38926030
[No Abstract] [Full Text] [Related]
9. Treatment of opioid overdose: current approaches and recent advances.
Britch SC; Walsh SL
Psychopharmacology (Berl); 2022 Jul; 239(7):2063-2081. PubMed ID: 35385972
[TBL] [Abstract][Full Text] [Related]
10. Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis.
Torralva R; Janowsky A
J Pharmacol Exp Ther; 2019 Nov; 371(2):453-475. PubMed ID: 31492824
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the rate of reversal of fentanyl-induced respiratory depression using a novel long-acting naloxone nanoparticle, cNLX-NP.
Averick SE; Kassick AJ; Song D; Zhang B; Vigliaturo J; Luengas D; Silva-Ortiz P; Pravetoni M; Raleigh MD
Front Psychiatry; 2024; 15():1366186. PubMed ID: 38550534
[TBL] [Abstract][Full Text] [Related]
12. Covalently Loaded Naloxone Nanoparticles as a Long-Acting Medical Countermeasure to Opioid Poisoning.
Kassick AJ; Wu M; Luengas D; Ebqa'ai M; Tharika Nirmani LP; Tomycz N; Nelson TL; Pravetoni M; Raleigh MD; Averick S
ACS Pharmacol Transl Sci; 2021 Oct; 4(5):1654-1664. PubMed ID: 34661081
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Profiling of Antifentanyl Monoclonal Antibodies in Combination with Naloxone in Pre- and Postexposure Models of Fentanyl Toxicity.
Baehr CA; Wu MM; Pandit SG; Arias-Umana J; AuCoin D; Pravetoni M
J Pharmacol Exp Ther; 2022 May; 381(2):129-136. PubMed ID: 35153198
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of naloxone and dexmedetomidine to simultaneously reverse acute effects of fentanyl and methamphetamine in rats.
Tackett WR; Yalakala J; Hambuchen MD
Drug Alcohol Depend; 2024 Jun; 259():111301. PubMed ID: 38640863
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
